Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans

被引:55
作者
Johnson, BA [1 ]
Ait-Daoud, N [1 ]
Wells, LT [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA
关键词
methamphetamine; isradipine; hypertension; calcium channel blockers; attention; cognition; humans;
D O I
10.1016/S0893-133X(99)00116-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
D-methamphetamine is abused for its euphoric effects and stimulatory action on cognitive function. Its abuse can, however, be associated with massive hypertension resulting in strokes, ruptured aneurysms, or myocardial infarction. We examined the utility of isradipine, a dihydropyridine-class calcium channel antagonist, in treating d-methamphetamine induced hypertension and evaluated its effects on cognitive function, both of which are mediated by dopaminergic mechanisms. D-methamphetamine dose-dependently increased all vital signs (systolic, diastolic, and mean arterial pressure, and pulse rate) parameters. Isradipine significantly reduced d-methamphetamine-induced increases in diastolic and mean arterial pressure; however, this potentially beneficial therapeutic effect was offset by a significant reflex rise in pulse rate, D-methamphetamine also improved attention, accuracy of reasoning ability, and performance on computerized cognitive function tasks. D-methamphetamine's cognitive improving effects were not altered significantly by isradipine. Isradipine increased the false responding rate but was without significant effect on any other attentional task, or on reasoning ability, or performance, Isradipine does not appear to enhance cognitive function in healthy humans. (C) 2000 American College of Neuropsychopharmacology.
引用
收藏
页码:504 / 512
页数:9
相关论文
共 54 条
[1]   Effect of NO synthesis inhibition on striatal dopamine release and stereotyped behavior induced by a single administration of methamphetamine [J].
Abekawa, T ;
Ohmori, T ;
Koyama, T .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1997, 21 (05) :831-838
[2]   EARLY PHARMACOKINETICS AND CLINICAL EFFECTS OF ORAL D-AMPHETAMINE IN NORMAL SUBJECTS [J].
ANGRIST, B ;
CORWIN, J ;
BARTLIK, B ;
COOPER, T .
BIOLOGICAL PSYCHIATRY, 1987, 22 (11) :1357-1368
[3]  
Apostolakos M J, 1996, New Horiz, V4, P45
[4]  
BADDELEY AD, 1968, PSYCHON SCI, V10, P341
[5]  
BAER PR, 1996, NEUROPSYCHIATRY OLD, P1
[6]  
BEEBE DK, 1995, AM FAM PHYSICIAN, V51, P449
[7]   Methamphetamine-induced alterations in dopamine transporter function [J].
Bennett, BA ;
Hollingsworth, CK ;
Martin, RS ;
Harp, JJ .
BRAIN RESEARCH, 1998, 782 (1-2) :219-227
[8]   CALCIUM-ANTAGONISTS AND MULTI-INFARCT DEMENTIA - A TRIAL INVOLVING SEQUENTIAL NMR AND PSYCHOMETRIC ASSESSMENT [J].
BESSON, JAO ;
PALIN, AN ;
EBMEIER, KP ;
EAGLES, JM ;
SMITH, FW .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1988, 3 (02) :99-105
[9]   ISRADIPINE - AN UPDATE OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION [J].
BROGDEN, RN ;
SORKIN, EM .
DRUGS, 1995, 49 (04) :618-649
[10]  
CARRARA V, 1994, EUR J CLIN PHARMACOL, V46, P29